Navigation Links
Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find
Date:10/14/2007

d Britschgi, who is also a first author of the paper. "The brain is part of the body and so it's connected in one huge network."

Reaching out to clinics in the United States, as well as Sweden, Poland and Italy, Britschgi obtained a total of 259 archived blood samples from individuals who had symptoms ranging from nothing abnormal to mild cognitive impairment to advanced Alzheimer's. Starting with 120 communication proteins, the team developed an analysis procedure to recognize if there was a pattern seen in Alzheimer's that could be compared with that of people without the condition. They discovered that as few as 18 proteins were sufficient to identify an Alzheimer's-specific pattern.

Among blood samples from 92 individuals who ranged from no symptoms to full dementia, the protein analysis matched the clinical diagnosis 90 percent of the time.

They then asked if they could predict the development of Alzheimer's among 47 people with mild cognitive impairment who had been followed from two to six years. The test - done on blood samples taken several years earlier - flagged 91 percent of the patients who developed Alzheimer's by the end of the follow-up time, as diagnosed by conventional methods.

"Already we have people approaching us at meetings asking if they can give us a vial of their grandfather's blood for testing," said Britschgi. Their findings show that it is possible to use factors in the blood to diagnose and even predict the disease, but, the authors emphasized, it must now be confirmed in other labs.

According to Satoris Inc, the company will develop a commercial Alzheimer's blood test, initially for use in research labs and, if confirmed as reliable, eventually as a clinical diagnostic test upon regulatory approval.

Britschgi and Wyss-Coray are interested in finding out why the cell communication pathways are altered in Alzheimer's. In their study, they determined that the 18 proteins that indicate
'/>"/>

Contact: Mitzi Baker
mabaker@stanford.edu
650-725-2106
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Infant receives first bloodless liver transplant
4. Spouses and other partners lower blood pressure says new research
5. H2O - a cure for low blood pressure
6. Uncontrolled blood pressure
7. Weight and Blood Pressure
8. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
9. Early diagnosis for autism from blood tests may be possible
10. Antibiotic from crab blood indentified
11. Gum disease may be caused by blood clotting gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...ents freedom of movement, better quality of life ,... An automated artificial kidney that can be worn ...at the insulin pump is to diabetes patients. , ...orks better than conventional dialysis, according ...xperimental Nephrology . , "What,s really new a...
(Date:7/25/2008)...wswire-USNewswire/ -- Anthony Shih,M.D., M.P.H., ...e President,of Strategic Planning, after a two-yea...ation committed to improving U.S. health system pe...ram on Health Care Quality,Improvement and Efficie.../20080725/DC28791LOGO ), Board-certified in publ...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...sumers tips and encourages them to, ,Speak Up,(TM...uly 25 /PRNewswire-USNewswire/ -- The Pennsylvania... Patient Safety Day" which,is a national effort to...ate fully in their healthcare by asking questions ...ry or illness., "We understand the important role...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...again in UK when it has been hit by a virus the se...farm in Yorkshire//. The Centre for Environment F...sed a report that states that scientists are study...ausing viral Haemorrhagic Septicaemia (VHS). <...
...archers at the University of Wisconsin-Madison it ... have more to pay later. // Super-sized meals whi... calories which help a person to gain more weight....s, health care and more. An average upsized fast-...
...al Center, has said that awareness needs to be cre...anger. // It has stated that it is not the program...anger of falling TV sets. UT Southwestern pediatri...ency department cases involving children injured b...
...BA) have entered into a partnership to support a g... The campaign, 'Unite for Children, Unite against...S on children as well as impeding further spread o...ow that our sport, indeed all sports, has an enorm...
Other Medicine News:Health News:Adults Needs to be Educated About the Dangers of Elevated TVs 2
(Date:7/23/2008)... July 23 /- InCode BioPharmaceutics, ... announced preclinical test,results demonstrating ...,the treatment of the rare chronic blood disorder ...plete results will be presented at the XXII,Intern... September 28,2008., The only treatment currentl...
(Date:7/23/2008)...d on IND-Enabling Work with Protein Therapeutics t...lement System, CAMBRIDGE, Mass., July 23 /PRNewsw...it has initiated a corporate growth plan with the,...cutive officer and the,establishment of its headqu...oodruff Emlen, M.D., a co-founder of the company w...
(Date:7/22/2008)...acy results from a multi-center 293-patient Europe... Stock Exchange Symbol: CYT, MONTREAL, July 22 /P...c., the global leader in cryotherapy products to t...ults previously presented from three,European stud... Front(R),were published earlier today in the Jou...
(Date:7/22/2008)...under Therapeutics Development Initiative bring MJ... next deadline January 20,2009, NEW YORK, July 2...n to,speed delivery of transformative treatments a...Fox Foundation for Parkinson,s Research has awarde...search teams. The awards,were granted under MJFF,s...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 1Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4Field Museum Launches Shared Bike Program for Employees 15487 1Field Museum Launches Shared Bike Program for Employees 15487 2
...SINESS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (A...loping,oral spray formulations for a broad range o...o clinical studies comparing zolpidem,oral spray w...cokinetic (PK), pharmacodynamic (PD) and safety ob...as Ambien(R), a leading,drug for the treatment of ...
... III Study Results Presented At ASCO -- , CHICAGO ...ith,pegylated interferon alfa-2b in stage III mela...apse-free survival (RFS),according to the results...atients with stage III melanoma. Results of the Ph...r the Research and,Treatment of Cancer (EORTC) and...
Other Medicine Technology:NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut
An easy to use uncomplicated ophthalmoscope.
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame.
Halberg Trial Clips have become a required addition to every refractive stand., ,These useful and inexpensive clips may be fitted over your patient's spectacle frame. Each cell has space for thre
Medicine Products: